Brokers Set Expectations for Neogen Co.’s Q1 2026 Earnings (NASDAQ:NEOG)

Neogen Co. (NASDAQ:NEOG) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Neogen in a research note issued to investors on Tuesday, September 10th. William Blair analyst B. Vazquez anticipates that the company will post earnings of $0.12 per share for the quarter. The consensus estimate for Neogen’s current full-year earnings is $0.54 per share. William Blair also issued estimates for Neogen’s Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $0.20 EPS.

Neogen (NASDAQ:NEOG) last released its earnings results on Tuesday, July 30th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). The company had revenue of $236.80 million for the quarter, compared to the consensus estimate of $225.83 million. Neogen had a negative net margin of 1.02% and a positive return on equity of 3.09%. The business’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 EPS.

Several other equities analysts also recently commented on NEOG. StockNews.com upgraded shares of Neogen to a “sell” rating in a report on Wednesday, September 4th. Piper Sandler increased their price target on Neogen from $17.00 to $17.50 and gave the stock a “neutral” rating in a report on Tuesday, August 6th.

Neogen Trading Up 1.6 %

Shares of NEOG opened at $15.50 on Thursday. The company’s fifty day simple moving average is $16.45 and its 200-day simple moving average is $15.21. The company has a market cap of $3.36 billion, a P/E ratio of 1,550.00 and a beta of 1.21. The company has a current ratio of 3.82, a quick ratio of 2.59 and a debt-to-equity ratio of 0.28. Neogen has a twelve month low of $11.46 and a twelve month high of $21.88.

Insider Transactions at Neogen

In related news, Director James P. Tobin purchased 3,000 shares of Neogen stock in a transaction that occurred on Tuesday, August 6th. The shares were bought at an average price of $16.86 per share, with a total value of $50,580.00. Following the purchase, the director now directly owns 23,392 shares of the company’s stock, valued at approximately $394,389.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NEOG. Covestor Ltd lifted its holdings in shares of Neogen by 173.2% in the 1st quarter. Covestor Ltd now owns 1,970 shares of the company’s stock worth $31,000 after buying an additional 1,249 shares during the period. Innealta Capital LLC purchased a new stake in Neogen in the second quarter worth about $46,000. Headlands Technologies LLC grew its holdings in Neogen by 264.1% during the 2nd quarter. Headlands Technologies LLC now owns 3,397 shares of the company’s stock worth $53,000 after acquiring an additional 2,464 shares in the last quarter. Family Firm Inc. purchased a new position in Neogen during the 2nd quarter valued at about $90,000. Finally, Quantum Private Wealth LLC purchased a new position in Neogen during the 2nd quarter valued at about $156,000. Institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.